Identifying pathogenic proteins leads to potential new treatments for diseases such as diabetes.

Published Date: 02 Mar 2023

New research has identified hundreds of proteins that can lead to the development of metabolic diseases, such as type 2 diabetes mellitus, and therefore have treatment potential.

Read Full News

Latest News

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Icodec-Semaglutide Combo Outperforms Glargine in T2D Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

Ultra-Rapid U500 Aspart AT278 Aids High-Dose T2D Therapy Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

Todays Updates

Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status Marco Meglio

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

NeurologyLive® Friday 5 — October 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

Is Pregnancy Riskier for Living Kidney Donors? With Amit X. Garg, MD, PhD Amit X. Garg, MD, PhD

A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.

Counseling Kidney Donors on Future Pregnancy, With Amit Garg, MD, PhD Amit X. Garg, MD, PhD

Future pregnancy plans don’t preclude living kidney donation, but candidates should be counseled on gestational hypertension risk.

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant

Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant

Todays Updates

Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status Marco Meglio

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

NeurologyLive® Friday 5 — October 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

Is Pregnancy Riskier for Living Kidney Donors? With Amit X. Garg, MD, PhD Amit X. Garg, MD, PhD

A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.

Counseling Kidney Donors on Future Pregnancy, With Amit Garg, MD, PhD Amit X. Garg, MD, PhD

Future pregnancy plans don’t preclude living kidney donation, but candidates should be counseled on gestational hypertension risk.

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant

Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant

Latest News

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

News All Time

FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD Rajiv Agarwal, MD, MS

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective.

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly Ryan Livingston

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

Survey Shows Peptide Misinformation, Misuse Rising in US Ashish Rana, MD

Ashish Rana, MD, discusses Sermo’s recent clinician survey, which highlighted patients’ use of unapproved and compounded GLP-1 medications.

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 Ryan Livingston

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials Ryan Livingston

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.
HTTP error: 503

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD John Anderson, MD

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Secret Shopper Study Reveals GLP-1 Telehealth Gaps Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.
HTTP error: 503

Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD Ryan Livingston

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes Marc P. Bonaca, MD, MPH

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

Insulin Icodec Now Available for Type 2 Diabetes in US Ryan Livingston

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

Recommended News For You

Why breast cancer survivors don't take their medicine, and what can be done about it.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

A new theranostic drug targets different cancer types.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

Are ultramarathon runners really at increased risk of bowel cancer?

Recommended Articles For You

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment 

Integrated Insights in Hematology and Quality Improvement 

Tumor Ecosystem Profiles for Therapy Matching 

Understanding Acute Myeloid Leukemia (AML) and Its Survival Rates 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

2.

healthy despite having advanced cancer.

3.

TKI Discontinuation Feasible After ALL Treatment

4.

De-escalation Misses the Mark in Inflammatory Breast Cancer

5.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

1.

Treating Methemoglobinemia: What You Need to Know Now!

2.

Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions

3.

Virtual Survivorship Platforms in Cancer Care: Transforming Post-Treatment Support and Outcomes

4.

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life

5.

Cancer Prehabilitation and Functional Recovery Pathways: An Evidence-Based Review

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

2.

Signs and Symptoms of Leukemia

3.

Efficient Management of First line ALK-rearranged NSCLC - Part III

4.

Navigating the Complexities of Ph Negative ALL - Part V

5.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot